Ablation of CD226 on CD4 + T cells modulates asthma progress associated with altered IL-10 response and gut microbiota

Yang Xie,Yuan Zhang,Tingting Wang,Yitian Liu,Jingchang Ma,Shuwen Wu,Chujun Duan,Wei Qiao,Kun Cheng,Lianjun Lu,Ran Zhuang,Ka Bian
DOI: https://doi.org/10.1016/j.intimp.2023.110051
IF: 5.714
2023-03-29
International Immunopharmacology
Abstract:To investigate the role of the costimulatory molecule CD226 in asthma pathogenesis, we produced a CD4 + T-cell-specific CD226 knockout mice model ( Cd226 ΔCD4 ) and induced airway allergic inflammation by administering ovalbumin (OVA). Our results revealed alleviated lung inflammation, decreased levels of OVA-specific IgE, and increased levels of IL-10 in the serum of Cd226 ΔCD4 mice ( P < 0.05). Moreover, IL-10 levels in CD4 + T cells were significantly elevated in the mediastinal lymph node, spleen, and Peyer's patches in the Cd226 ΔCD4 mice compared with those in controls ( P < 0.05 to P < 0.01). Notably, there was a significantly higher IL-10 mRNA levels in the large intestine of the mice ( P < 0.05). The protective effect of CD226 deficiency is also associated with the accumulation of gut TCRγδ + intraepithelial lymphocytes and reversion of the gut microbiome dysbiosis. The Bacteroidetes-to-Firmicutes ratio and the abundance of Akkermansia increased in the absence of CD226 after OVA treatment. Our data reveal the synchronous changes in the lung and intestine in OVA-treated CD226-knockout mice, supporting the gut–lung axis concept and providing evidence for novel therapeutic approaches for asthma.
pharmacology & pharmacy,immunology
What problem does this paper attempt to address?